Search research articles
Contact Us
Filters
Showing results (41-50 of 51) with videos related to
Page
of 6
Sort By:
BMJ Open
|
May 29, 2021
Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson's disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The 'Exenatide-PD3' study
Nirosen Vijiaratnam, Christine Girges, Grace Auld, et al.
NPJ Parkinson'S Disease
|
November 24, 2022
Protein aggregation and calcium dysregulation are hallmarks of familial Parkinson's disease in midbrain dopaminergic neurons
Gurvir S Virdi, Minee L Choi, James R Evans, et al.
Annals of Neurology
|
July 29, 2025
Exenatide Once Weekly in the Treatment of Patients with Multiple System Atrophy
Nirosen Vijiaratnam, Christine Girges, Martin Wiegand, et al.
Nature Neuroscience
|
August 30, 2022
Pathological structural conversion of α-synuclein at the mitochondria induces neuronal toxicity
Minee L Choi, Alexandre Chappard, Bhanu P Singh, et al.
Nature Neuroscience
|
October 19, 2022
Author Correction: Pathological structural conversion of α-synuclein at the mitochondria induces neuronal toxicity
Minee L Choi, Alexandre Chappard, Bhanu P Singh, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
April 18, 2025
Treatment Selection and Prioritization for the EJS ACT-PD MAMS Trial Platform
Cristina Gonzalez-Robles, Dilan Athauda, Thomas R Barber, et al.
Science Advances
|
April 11, 2025
Astrocytic RNA editing regulates the host immune response to alpha-synuclein
Karishma D'Sa, Minee L Choi, Aaron Z Wagen, et al.
Lancet (London, England)
|
February 7, 2025
Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial
Nirosen Vijiaratnam, Christine Girges, Grace Auld, et al.
Eclinicalmedicine
|
August 17, 2021
Antiphospholipid antibodies and neurological manifestations in acute COVID-19: A single-centre cross-sectional study
Laura A Benjamin, Ross W Paterson, Rachel Moll, et al.
Brain Communications
|
August 16, 2021
Serum and cerebrospinal fluid biomarker profiles in acute SARS-CoV-2-associated neurological syndromes
Ross W Paterson, Laura A Benjamin, Puja R Mehta, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 51) with videos related to
Sort By:
Page
of 6
BMJ Open
|
May 29, 2021
Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson's disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The 'Exenatide-PD3' study
Nirosen Vijiaratnam, Christine Girges, Grace Auld, et al.
NPJ Parkinson'S Disease
|
November 24, 2022
Protein aggregation and calcium dysregulation are hallmarks of familial Parkinson's disease in midbrain dopaminergic neurons
Gurvir S Virdi, Minee L Choi, James R Evans, et al.
Annals of Neurology
|
July 29, 2025
Exenatide Once Weekly in the Treatment of Patients with Multiple System Atrophy
Nirosen Vijiaratnam, Christine Girges, Martin Wiegand, et al.
Nature Neuroscience
|
August 30, 2022
Pathological structural conversion of α-synuclein at the mitochondria induces neuronal toxicity
Minee L Choi, Alexandre Chappard, Bhanu P Singh, et al.
Nature Neuroscience
|
October 19, 2022
Author Correction: Pathological structural conversion of α-synuclein at the mitochondria induces neuronal toxicity
Minee L Choi, Alexandre Chappard, Bhanu P Singh, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
April 18, 2025
Treatment Selection and Prioritization for the EJS ACT-PD MAMS Trial Platform
Cristina Gonzalez-Robles, Dilan Athauda, Thomas R Barber, et al.
Science Advances
|
April 11, 2025
Astrocytic RNA editing regulates the host immune response to alpha-synuclein
Karishma D'Sa, Minee L Choi, Aaron Z Wagen, et al.
Lancet (London, England)
|
February 7, 2025
Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial
Nirosen Vijiaratnam, Christine Girges, Grace Auld, et al.
Eclinicalmedicine
|
August 17, 2021
Antiphospholipid antibodies and neurological manifestations in acute COVID-19: A single-centre cross-sectional study
Laura A Benjamin, Ross W Paterson, Rachel Moll, et al.
Brain Communications
|
August 16, 2021
Serum and cerebrospinal fluid biomarker profiles in acute SARS-CoV-2-associated neurological syndromes
Ross W Paterson, Laura A Benjamin, Puja R Mehta, et al.
Page
of 6